Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Müller C, Hackl F, Rainer W, Watkins-Riedel T, Lin W, Krejs GJ, Gangl A; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: muller c. Eur J Gastroenterol Hepatol. 2001 Jun;13(6):699-705. doi: 10.1097/00042737-200106000-00014. Eur J Gastroenterol Hepatol. 2001. PMID: 11434597 Clinical Trial.
Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P, Stauber R, Propst A, Fiedler R, Müller C, Gschwantler M, Schütze K, Datz C, Judmaier G, Vogel W, Krejs GJ, Gangl A. Ferenci P, et al. Among authors: muller c. Dig Dis Sci. 1996 Dec;41(12 Suppl):103S-108S. doi: 10.1007/BF02087884. Dig Dis Sci. 1996. PMID: 9011466 Clinical Trial.
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Müller C, Hackl F, Rainer W, Watkins-Riedel T, Lin W. Ferenci P, et al. Among authors: muller c. J Viral Hepat. 1999 Jul;6 Suppl 1:53-8. doi: 10.1046/j.1365-2893.1999.00005.x. J Viral Hepat. 1999. PMID: 10760037 Clinical Trial.
Long-term follow-up in cerebral Whipple's disease.
Schnider PJ, Reisinger EC, Gerschlager W, Müller C, Berger T, Krejs GJ, Auff E. Schnider PJ, et al. Among authors: muller c. Eur J Gastroenterol Hepatol. 1996 Sep;8(9):899-903. Eur J Gastroenterol Hepatol. 1996. PMID: 8889458 Review.
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
Müller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P. Müller C, et al. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70. doi: 10.1097/00042737-199810000-00010. Eur J Gastroenterol Hepatol. 1998. PMID: 9831410 Clinical Trial.
7,481 results